Mirum Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Mirum Pharmaceuticals Inc.
Ownership: Public
Status: Active
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Foster City
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: MIRM
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001759425
EIN: 83-1281555

Board of directors

Follow this board

Christopher Peetz · Director · CHIEF EXECUTIVE OFFICER
Since 2023
Laura Brege · Director
Since 2023
Laurent Fischer · Director
Since 2023
Lon Cardon · Director
Since 2023
Michael G. Grey · Director
Since 2023
Patrick J. Heron · Director
Since 2023
Saira Ramasastry · Director
Since 2023
Timothy P. Walbert · Director Overboarded
Since 2023
William Fairey · Director
Since 2023

Chief executives

Christopher Peetz · CHIEF EXECUTIVE OFFICER

Dates unknown

Director election results

Annual meeting of June 15, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Timothy P. Walbert

69.7%
William Fairey

86.8%

Board connections

7 of this board's directors also sit on 17 other boards.

Shared director Other board Same sector +1 more in the list below

Arcutis Biotherapeutics Inc.
via Christopher Peetz and Patrick J. Heron
ACADIA Pharmaceuticals Inc.
via Laura Brege
Ascendis Pharma A/S
via William Fairey
BioMarin Pharmaceutical Inc.
via Timothy P. Walbert
Century Therapeutics Inc.
via Timothy P. Walbert
Edgewise Therapeutics Inc.
via Laura Brege
Faeth Therapeutics Inc.
via Saira Ramasastry
Kardigan Inc.
via Timothy P. Walbert
Latigo Biotherapeutics Inc.
via Timothy P. Walbert
MBX Biosciences Inc.
via Patrick J. Heron
Odyssey Therapeutics Inc.
via Timothy P. Walbert
OnKure Therapeutics Inc.
via Michael G. Grey
Pacira BioSciences Inc.
via Laura Brege
Rein Therapeutics Inc.
via William Fairey
Sagimet Biosciences Inc.
via Timothy P. Walbert
Spruce Biosciences Inc.
via Michael G. Grey
Vir Biotechnology Inc.
via Saira Ramasastry

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $8,999,984; 1 purchase by 1 insider
Sold, last 12 months: $42,201,978; 59 sales by 7 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 14, 2026	Eric Bjerkholt Officer (CHIEF FINANCIAL OFFICER)	Open-market sale	−9,943	$98.37	$978,093
Sep 11, 2026	Eric Bjerkholt Officer (CHIEF FINANCIAL OFFICER)	Option exercise	+18,333	—	—
Sep 2, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Open-market sale	−658	$100.00	$65,800
Sep 1, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+30,000	$2.94	$88,080
Sep 1, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−8,312	$98.08	$815,241
Sep 1, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−21,688	$98.91	$2,145,160
Aug 18, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Option exercise	+40,000	$6.27	$250,800
Aug 18, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Open-market sale	−40,000	$100.00	$4,000,000
Aug 11, 2026	Eric Bjerkholt Officer (CHIEF FINANCIAL OFFICER)	Open-market sale	−6,001	$99.90	$599,510
Aug 10, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+20,000	$2.94	$58,720
Aug 10, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−11,683	$98.51	$1,150,892
Aug 10, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−6,017	$99.25	$597,187
Aug 10, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−2,300	$100.14	$230,322
Aug 3, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Open-market sale	−1,840	$105.29	$193,734
Jul 6, 2026	Eric Bjerkholt Officer (CHIEF FINANCIAL OFFICER)	Open-market sale	−3,124	$121.67	$380,097

Reviews (0)

No reviews yet. Be the first to write one.